Sarecycline

Sarecycline

Clinical data
Pronunciation	sar"e sye' kleen
Trade names	Seysara
Other names	P-005672
AHFS/Drugs.com	Monograph
MedlinePlus	a618068
License data	US DailyMed: Sarecycline
Routes of administration	By mouth
ATC code	J01AA14 (WHO) J01AA20 (WHO)
Legal status
Legal status	US: ℞-only
Identifiers
IUPAC name (4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide
CAS Number	1035654-66-0
PubChem CID	54681908 as HCl: 71296095
DrugBank	DB12035 as HCl: DBSALT002125
ChemSpider	28540486
UNII	94O110CX2E
KEGG	D10666 as HCl: D10667
ChEMBL	ChEMBL2364632
PDB ligand	V7A (PDBe, RCSB PDB)
ECHA InfoCard	100.241.852
Chemical and physical data
Formula	C24H29N3O8
Molar mass	487.509 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC

Sarecycline, sold under the brand name Seysara , is a narrow-spectrum tetracycline-derived antibiotic medication. It is specifically designed for the treatment of acne, and was approved by the FDA in October 2018 for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Two randomized and well-controlled clinical trials reported efficacy data on both facial and truncal acne (back and chest). Efficacy was assessed in a total of 2002 subjects 9 years of age and older. Unlike other tetracycline-class antibiotics, sarecycline has a long C7 moiety that extends into and directly interact with the bacterial messenger RNA (mRNA). The spectrum of activity is limited to clinically relevant Gram-positive bacteria, mainly Cutibacterium acnes, with little or no activity against Gram-negative bacterial microflora commonly found in the human gastrointestinal tract.

Medical uses

Sarecycline, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.